查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1247468

2023-2030 年全球生命科学仪器市场

Global Life Science Instrumentation Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球生命科学仪器市场预计到 2022 年将达到 560 亿美元，到 2030 年将达到 1070 亿美元。 在预测期内（2023-2030 年），该市场将以 7.9% 的复合年增长率增长。

为了最大限度地提高产量并保持过程控制，生命科学，尤其是生物技术、製药和医疗设备，需要可靠且准确的仪器。 用于调节和监控过程以及评估製造工厂的产品质量的仪器被称为生命科学仪器。 它通常被视为物理学、工程学和生物科学的融合。 在生物技术领域，它是分子生物学和生物体科学研究的重要工具。

市场动态

药物研发投入增加。

生物技术和製药等公司正在大力投资研发。 这是由对快速药物开发和用于治疗罕见疾病的新型药理化合物商业化的日益增长的需求所推动的。

世界的疾病负担和不断上升的研发成本从根本上推动了对生命科学仪器的需求。 此外，製药行业增加对药物发现和开发的投资将增加对用于药物验证的生命科学工具的需求。 增加对生命科学研究的公共和私人投资以及分析仪器技术的进步正在推动生命科学仪器和化学品的市场。

例如，根据英国议会在2022年10月发布的一篇文章，英国在2022年的研发支出总额为375亿欧元。 此外，根据经合组织数据，2021年药品占GDP的比重将在保加利亚最高，约为33.0%。 因此，由于研发活动的医药支出增加，预计市场将扩大。

某些类型的癌症产品可以使用基于生命科学设备的药物进行有效治疗。 这可以降低发展中国家和欠发达国家的医疗保健成本。 随着全球癌症患者数量的增加，生命科学仪器市场有望增长。

设备的高成本可能会阻碍市场增长。

生命科学仪器市场的发展将受到仪器成本高、缺乏合格劳动力、qPCR 和 dPCR 程序的技术限制以及高性能显微镜的高成本的限制。 另一方面，新兴国家缺乏研究基础设施和价格压力可能会威胁到市场扩张。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按产品分类的片段
  • 按技术分类的片段
  • 区域摘要

第 4 章动力学

  • 影响因子
    • 司机
      • 扩大对生命科学研究的公私合作资助
      • 慢性病越来越普遍
    • 约束因素
      • 设备成本高阻碍了市场增长
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章技术

  • 光谱学
  • 聚合□炼式反应 (PCR)
  • 色谱法
  • 流式细胞仪
  • 电泳
  • 离心机
  • 其他

第八章应用

  • 调查
  • 临床/诊断

第 9 章：结束

  • 製药和生物技术公司
  • 农业和食品行业
  • 医院/诊断中心

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 俄罗斯
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 竞争场景
  • 市场分析/份额分析
  • 併购分析

第12章公司简介

  • Bio-Rad 实验室公司
    • 公司简介
    • 产品组合和说明
    • 财务摘要
    • 主要发展
  • Agilent Technologies Inc
  • PerkinElmer, Inc
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • JEOL Ltd
  • Shimadzu Corporation
  • Becton, Dickinson & Company
  • HORIBA, Ltd.,
  • Bruker Corporation

第13章 附录

简介目录
Product Code: MD1529

Market Overview

The global Life Science Instrumentation market reached US$ 56,000 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 107,000 million by 2030. The market is growing at a CAGR of 7.9% during the forecast period (2023-2030).

To maximize yields and maintain process control, life sciences, particularly biotechnology, pharmaceuticals, and medical devices, need dependable and accurate instrumentation. The equipment used to regulate and monitor the process in manufacturing plants, as well as to assess the quality of the products, is known as life science instrumentation. It is generally seen as the fusion of physics, engineering, and biological sciences. In the realm of biotechnology, these tools are essential for the scientific examination of molecular biology and living things.

Market Dynamics

The increasing investments spending on pharmaceutical research and development.

In companies like biotechnology and pharmaceuticals, there is a large investment in R&D. The increased desire for quick medication development and the commercialization of novel pharmacological compounds for the treatment of uncommon illnesses are to blame for this.

The burden of illness in the world and rising R&D costs are what essentially drive the demand for life science devices. Also, there will likely be a rise in demand for life science tools for drug validation due to the pharmaceutical industry's growing investment in drug discovery and development. Growing public-private investments in life science research as well as advancements in analytical equipment technology are driving the market for life science instruments and chemicals.

For instance, according to an article released by the UK Parliament in October 2022, the UK spent a total of EUR 37.5 billion on research and development in 2022. Also, according to OECD data, Bulgaria spent the most on pharmaceuticals as a proportion of GDP in 2021, at about 33.0%. Hence, it is anticipated that market expansion will be aided by rising pharmaceutical spending on R&D activities.

A certain Product of cancer can be effectively treated using drugs based on Life Science Instrumentation. This lowers the cost of healthcare for developing and underdeveloped nations. The Life Science Instrumentation market should grow as cancer cases rise globally.

The high cost of instruments will hamper the growth of the market.

The development of the life science instrumentation market will be constrained by the high cost of instruments, a shortage of competent labor, technological limitations on qPCR and dPCR procedures, and the high cost of sophisticated microscopes. On the other hand, the expansion of the market can be threatened by the absence of research infrastructure in developing countries and price pressure.

Segment Analysis

The global Life Science Instrumentationmarket is segmented based on technology, application, end user and region.

The technology segment is expected to grow at the fastest CAGR during the forecast period(2023-2030)

Based on technology, the global Life Science Instrumentation market is segmented into Spectroscopy, Polymerase Chain Reaction (PCR), Chromatography, Flow Cytometry, Electrophoresis, Centrifuges and Others. Among these, The DNA polymerase's ability to build new DNA strands that are supporting to the provide template strand forms the basis of PCR. DNA polymerase requires a primer on which it may add the first nucleotide since it can only add a nucleotide onto an already-existing 3'-OH group.

This prerequisite allows the researcher to identify a particular area of the template sequence that they want to amplify. The specified sequence will accumulate in billions of copies at the end of the PCR cycle (amplicons). The segment is driven by the increasing prevalence of chronic and infectious diseases as well as the rising demand for precise and expedient disease diagnosis methods. Also, the segment is being driven by the development of technologically improved products and an increase in healthcare expenditure.

For instance, on January 2022, during Arab Health 2022, Irish diagnostics company HiberGene Diagnostics will introduce its PCR Adapt COVID-19 test. Ireland's leading manufacturer, developer, and producer of Molecular Diagnostics products is HiberGene, which holds an ISO certification. HiberGene's elite team created the ground-breaking PCR Adapt COVID-19 test as part of a plan to diversify the company's line of products.

On Feburaury 2023, To further advance healthcare and innovation in the Kingdom of Saudi Arabia, Tamer Healthcare, an integrated healthcare and wellness company with more than 100 years of established business in the Kingdom of Saudi Arabia, and Digital Diagnostics, the company behind IDx-DR, the first-ever FDA-cleared, fully autonomous AI system for the diagnosis of diabetic retinopathy, have announced a strategic partnership.

Geographical Penetration

The expansion of the industry is being facilitated by an increase in R&D efforts.

North America has established itself as the dominant market participant in the Life Science Instrumentations market. Life science and chemical instrumentation technology are used extensively in the pharmaceutical and biotechnology sectors in North America. Chemical instrumentation has shown to be an effective technological tool for a number of uses, including final production testing, pharmaceutical applications, environmental monitoring, and food testing.

Also, the expansion of the industry is being facilitated by an increase in R&D efforts. For instance, according to a 2021 update from the University of North Dakota, the National Institutes of Health (NIH) will continue to support the project through Phase II, according to the UND Center of Biomedical Research Excellence (CoBRE) in Host-Pathogen Interactions (HPI). The renewal of USD 10.7 million aims to further knowledge of how the body reacts to bacterial, viral, and parasitic infections that lead to acute and long-term inflammatory disorders. Thus, it is anticipated that increased R&D investment for various life sciences-related research will spur market expansion over the projection period.

Competitive Landscape

The major global players include Bio-Rad Laboratories Inc, Agilent Technologies Inc, PerkinElmer, Inc, F. Hoffmann-La Roche Ltd., Danaher Corporation, JEOL Ltd, Shimadzu Corporation, Becton, Dickinson & Company, HORIBA, Ltd. and Bruker Corporation.

COVID-19 Impact Analysis

By Technology

  • Spectroscopy
  • Polymerase Chain Reaction (PCR)
  • Chromatography
  • Flow Cytometry
  • Electrophoresis
  • Centrifuges
  • Others

By Application

  • Research
  • Clinical and Diagnostic

By End user

  • Pharma-Biotech
  • Agri and Food Industry
  • Hospitals & Diagnostic Labs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2022, A novel Fourier transform infrared spectrophotometer called the IRXross has been made available by Shimadzu Company. The sensitivity and resolution of this model are around twice as high as those of the IRAffinity-1S, its forerunner. The addition of the IR Pilot, an analytical help application that even novice users may use, has increased usability.
  • In October, 2021, SFDA has now approved a COVID-19 RT-PCR test that was developed by KAUST and first utilized in the United Kingdom. The service was launched at KAUST Health by KAUST company Noor DX. Noor DX offers a broad range of processing equipment using biotech diagnostics and is located in the Core Laboratories at KAUST. In the fight against COVID-19, this novel RT-PCR has the potential to be a game-changer, not just for Saudi Arabia but also for other nations looking for affordable, easily implemented diagnostics.
  • On August 2022, an agreement to acquire all of Curiosity Diagnostics' outstanding shares was announced by Bio-Rad Laboratories, Inc., a pioneer in life science research and clinical diagnostic products. For the molecular diagnostics business, Curiosity Diagnostics, a late-stage, pre-commercial platform company, is developing a sample-to-answer PCR system.

Why Purchase the Report?

  • To visualize the global Life Science Instrumentation- marketsegmentation based on Product, Technology, and region,as well as understandkey commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerousdata points of Life Science Instrumentationmarket-level with allsegments.
  • PDF report consists of a comprehensiveanalysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key productsof all the major players.

The global Life Science Instrumentationmarketreport would provide approximately 53 tables,54figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Expanding public-private funding for life science research
      • 4.1.1.2. Increasing prevalence of chronic illnesses.
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. The high cost of instruments will hamper the growth of the market.
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. XX
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. PostCOVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. ByTechnology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Spectroscopy *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Polymerase Chain Reaction (PCR)
  • 7.4. Chromatography
  • 7.5. Flow Cytometry
  • 7.6. Electrophoresis
  • 7.7. Centrifuges
  • 7.8. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByTechnology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Research *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinical and Diagnostic

9. By End suer

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByTechnology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. Pharmaceutical and Biotechnology Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Agri and Food Industry
  • 9.4. Hospitals & Diagnostic Labs

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis andY-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis andY-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Russia
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bio-Rad Laboratories Inc
    • 12.1.1. Company Overview
    • 12.1.2. ProductPortfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Agilent Technologies Inc
  • 12.3. PerkinElmer, Inc
  • 12.4. F. Hoffmann-La Roche Ltd.
  • 12.5. Danaher Corporation
  • 12.6. JEOL Ltd
  • 12.7. Shimadzu Corporation
  • 12.8. Becton, Dickinson & Company
  • 12.9. HORIBA, Ltd.,
  • 12.10. Bruker Corporation

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us